Generic Antineoplastic / Chemotherapeutic agent / Anthracyclines
Generic Antineoplastic / Chemotherapeutic agent / Anthracyclines Companies (8)
Generic Antineoplastic / Chemotherapeutic agent / Anthracyclines News
-
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries.
Generic Antineoplastic / Chemotherapeutic agent / Anthracyclines Products (22)
-
Product Pazopanib hydrochloride-API
• High-purity active pharmaceutical ingredient engineered for pazopanib-based formulations. • Offered as a fine crystalline powder with robust purity and consistent physicochemical properties. • Produced under rigorous cGMP standards to ensure batch-to-batch reproducibility and quality assurance. • Sub... -
Product APIs
• Paclitaxel (Package : Up to 500g Per request) • Pemetrexed (Package : Up to 1kg Per request) • Bortezomib (Package : Up to 40g Per request) -
Product Erdafitinib
Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuva... -
Product Oncology API# Bulk Sterile # General API
ONCOLOGY : Cytarabine Gemcitabine Pemetrexate Paclitaxel Letrozole Irrinotecane Bicalutamide Gefitinib Etoposide Anastrazole Dacarbazine Bulk Sterile : Methyle prednisolone Hydrocortisone Pantoprazole Chloramphenicol Colistimethate Polymyxin B Gluthatione General API Suxamethonium Ropivaccaine Neostigmine... -
Product Sunitinib malate-API
• High-quality active pharmaceutical ingredient developed for sunitinib-based formulations. • Provided as a fine crystalline powder with exceptional purity and consistent physicochemical attributes. • Manufactured under strict cGMP conditions to ensure uniform quality and batch-to-batch reproducibility.... -
Product Letrozole-API
• High-quality active pharmaceutical ingredient designed for letrozole-based formulations. • Provided as a highly purified, white crystalline powder with consistent physicochemical properties. • Manufactured under strict cGMP conditions to ensure reliable quality and batch-to-batch reproducibility. • E... -
Product Lenalidomide hemihydrate-API
• High-quality active pharmaceutical ingredient designed for lenalidomide hemihydrate formulations. • Manufactured under stringent cGMP conditions to ensure batch-to-batch reproducibility and high quality. • Extensively characterized using advanced analytical techniques such as HPLC, NMR, and LC-MS for ... -
Product Imatinib Mesylate-API
• Premium-grade active pharmaceutical ingredient intended for imatinib-based formulations. • Selectively targets the BCR-ABL tyrosine kinase, crucial for managing chronic myelogenous leukemia and gastrointestinal stromal tumors. • Supplied as a highly purified crystalline powder with excellent physicoch... -
Product Gefitinib-API
• High-quality active pharmaceutical ingredient developed for gefitinib-based formulations. • Selective EGFR tyrosine kinase inhibitor designed to block aberrant cancer cell signaling. • Offered as a fine, crystalline powder with excellent purity and consistent physicochemical properties. • Manufacture... -
Product Erlotinib hydrochloride-API
• High-purity active pharmaceutical ingredient developed for erlotinib-based formulations. • Potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, essential for targeting aberrant cancer cell signaling. • Supplied as a fine crystalline powder with excellent physicochemical sta... -
Product Dasatinib anhydrous/monohydrate-API
• High-purity active pharmaceutical ingredient designed for the manufacture of dasatinib-based formulations. • A potent multi-targeted tyrosine kinase inhibitor effective against BCR-ABL and Src family kinases. • Exhibits robust inhibitory activity, making it a critical component in treatments for CML a... -
Product Abiraterone acetate-API
• High-purity active pharmaceutical ingredient formulated for the production of abiraterone acetate dosage forms. • Effectively inhibits CYP17, contributing to reduced androgen synthesis in prostate cancer therapies. • Presented as a white to off-white crystalline powder that meets strict quality standa... -
Product CDMO
• Cytotoxic Injection (Liquid , Lyophilized) • ONCOLOGY • CYTOTOXIC API • EU GMP • JGMP (Japan) • KGMP (Korea) • PIC/S -
Product Everolimus
Indicated for Prophylaxis of Organ Rejection in Kidney Transplantation and Prophylaxis of Organ Rejection in Liver Transplantation -
Product Ixazomib Citrate
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. -
Product Midostaurin
Indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test -
Product Binimetinib
Indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation -
Product Fulvestrant
Indicated for the treatment of Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression... -
Product INJECTIONS
Albumin bound Paclitaxel Inj Azacitadine Inj Bendamustin Inj Bortezomib Inj Busulfan Inj Carboplatin Inj Carfilzomib Inj Carmustin Inj Cisplatin Inj Cytrabine Inj Dacarbazine Inj Dactinomycin Inj Degrarelix Inj Doceteaxel Inj Doxorubicin Inj Epirubicin Inj Eribulin Inj Etoposide Inj Fludarabine Inj Fosapre...
Upcoming Events
-
CPHI Japan 2025
East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan
09 Apr 2025 – 11 Apr 2025 -
CPHI Americas 2025
Pennsylvania Convention Center, Philadelphia
20 May 2025 - 22 May 2025 -
CPHI & PMEC China 2025
Shanghai New International Expo Center
24 Jun 2025 - 26 Jun 2025
Pharmaceutical Industry Webinars
Recommended Products And News
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance